Literature DB >> 17904793

Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS).

J E Eyles1, M G Hartley, T R Laws, P C F Oyston, K F Griffin, R W Titball.   

Abstract

BALB/c mice were immunised with inactivated Francisella tularensis live vaccine strain (LVS) and the level of protection afforded against aerosol challenge with virulent strains of F. tularensis ascertained. Intramuscular (IM) injection of inactivated LVS with an aluminium-hydroxide-based adjuvant-stimulated IgG1-biased LVS-specific antibody responses and afforded no protection against aerosol challenge with subspecies holarctica (strain HN63). Conversely, IM injection of inactivated LVS adjuvanted with preformed immune-stimulating complexes (ISCOMS) admixed with immunostimulatory CpG oligonucleotides afforded robust protection against aerosol-initiated infection with HN63. However, despite a significantly extended time-to-death relative to naïve controls, the majority of mice immunised with the most potent vaccine formulation were not protected against a low-dose aerosol challenge with subspecies tularensis (strain Schu S4). These data indicate that parenterally administered non-living vaccines can be used for effective immunisation against aerosol challenges with subspecies holarctica, although not high virulence strains of F. tularensis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904793     DOI: 10.1016/j.micpath.2007.08.009

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  18 in total

1.  Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

Authors:  Stephen H Gregory; Wilbur H Chen; Stephanie Mott; John E Palardy; Nicholas A Parejo; Sara Heninger; Christine A Anderson; Andrew W Artenstein; Steven M Opal; Alan S Cross
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

2.  Mouse models of aerosol-acquired tularemia caused by Francisella tularensis types A and B.

Authors:  David L Fritz; Marilyn J England; Lynda Miller; David M Waag
Journal:  Comp Med       Date:  2014-10       Impact factor: 0.982

3.  A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens.

Authors:  Michael D Valentino; C Siddiq Abdul-Alim; Zachary J Maben; Denise Skrombolas; Lucinda L Hensley; Thomas H Kawula; Michelle Dziejman; Edith M Lord; Jeffrey A Frelinger; John G Frelinger
Journal:  J Immunol Methods       Date:  2011-08-18       Impact factor: 2.303

4.  Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS.

Authors:  Michael D Valentino; Lucinda L Hensley; Denise Skrombolas; Pamela L McPherson; Matthew D Woolard; Thomas H Kawula; Jeffrey A Frelinger; John G Frelinger
Journal:  Mol Immunol       Date:  2009-02-23       Impact factor: 4.407

5.  Infected-host-cell repertoire and cellular response in the lung following inhalation of Francisella tularensis Schu S4, LVS, or U112.

Authors:  Joshua D Hall; Matthew D Woolard; Bronwyn M Gunn; Robin R Craven; Sharon Taft-Benz; Jeffrey A Frelinger; Thomas H Kawula
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

Review 6.  Tularemia vaccines.

Authors:  Daniela Putzova; Iva Senitkova; Jiri Stulik
Journal:  Folia Microbiol (Praha)       Date:  2016-05-19       Impact factor: 2.099

7.  Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia.

Authors:  Damiana Chiavolini; Susan Weir; John R Murphy; Lee M Wetzler
Journal:  Clin Vaccine Immunol       Date:  2008-07-09

8.  Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis.

Authors:  Jason F Huntley; Patrick G Conley; David A Rasko; Kayla E Hagman; Michael A Apicella; Michael V Norgard
Journal:  Infect Immun       Date:  2008-05-27       Impact factor: 3.441

9.  Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strains.

Authors:  Terry H Wu; Jason L Zsemlye; Gloria L Statom; Julie A Hutt; Ronald M Schrader; Alexandra A Scrymgeour; C Rick Lyons
Journal:  Vaccine       Date:  2009-06-09       Impact factor: 3.641

10.  CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-γ responses.

Authors:  Michael J McCluskie; Risini D Weeratna; Dana M Evans; Shawn Makinen; Debbie Drane; Heather L Davis
Journal:  Biomed Res Int       Date:  2013-03-23       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.